PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo

The efficacy of targeting the MAPK signaling pathway in patients with melanoma is limited by the rapid development of resistance mechanisms that result in disease relapse. In this article, we focus on targeting the DNA repair pathway as an antimelanoma therapy, especially in MAPK inhibitor resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Fröhlich, Lisa Marie, Niessner, Heike, Sauer, Birgit, Kämereit, Sofie, Chatziioannou, Eftychia, Riel, Simon, Sinnberg, Tobias, Schittek, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478790/
https://www.ncbi.nlm.nih.gov/pubmed/37674529
http://dx.doi.org/10.1158/2767-9764.CRC-23-0101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478790/
https://www.ncbi.nlm.nih.gov/pubmed/37674529
http://dx.doi.org/10.1158/2767-9764.CRC-23-0101

Ejemplares similares